Millennium Pharmaceuticals, Inc.

Quick facts

Marketed products

• Oral cholera vaccine

Phase 3 pipeline

• TAK-788 · Oncology
  TAK-788 is a selective inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
• VELCADE Administered by intravenous infusion · Oncology
  VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.
• VELCADE Administered by subcutaneous injection · Oncology
  VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death.

Phase 2 pipeline

• bortezomib, dexamethasone, and thalidomide
• bortezomib, dexamethasone, thalidomide, and cyclophosphamide
• LDP-02
• TAK-906 Maleate
• TAK-931 Tablet
• VELCADE and rituximab

Phase 1 pipeline

• [^14C]-alisertib
• [14C]-Pevonedistat
• [14C]-TAK-906 Intravenous Infusion
• [14C]-TAK-906 Oral Solution
• [14C]-TAK-954
• [68Ga]MLN6907
• bortezomib, rifampicin
• Brentuximab vedotin and rifampicin
• CT53518
• MLN2480
• MLN518
• omeprazole and bortezomib
• TAK-285 Dose Escalation Cohorts
• TAK-701
• TAK-931 PIC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Millennium Pharmaceuticals, Inc. portfolio CI brief
• Millennium Pharmaceuticals, Inc. pipeline updates RSS